IQVIA Holdings Inc. Stock
Price
Target price
€218.50
€218.50
-0.790%
-1.7
-0.790%
-
18.09.24 / Tradegate
WKN: A2JSPM / Name: IQVIA / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
IQVIA Holdings Inc. Stock
IQVIA Holdings Inc. shows a slight decrease today, losing -€1.700 (-0.790%) compared to yesterday.
For the coming years our community has positive and negative things to say abot the IQVIA Holdings Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of IQVIA Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of IQVIA Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| IQVIA Holdings Inc. | -0.790% | 2.438% | 0.552% | 11.480% | 4.296% | 0.092% | 58.127% |
| Incyte Corp. | 1.160% | 2.408% | 4.079% | 5.350% | 3.419% | -9.444% | -17.573% |
| Regeneron Pharmaceuticals Inc. | 1.270% | -0.966% | -4.204% | 32.923% | 28.589% | 84.808% | 296.789% |
| Exact Sciences | 1.860% | 7.077% | 17.005% | -11.499% | -9.033% | -32.401% | -34.770% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
The financials of IQVIA, a prominent entity in the Biotechnology and Medical Research industry, reflect a complex blend of strengths and challenges. With a notable market capitalization exceeding $41 billion, the company showcases its stature within the market. Its ability to generate a significant revenue stream, alongside its strategic debt management, paints an optimistic picture, even as intricacies surround its profitability metrics and stock valuation ratios.
Analyzing the financials of IQVIA reveals several pros and cons that can guide investors and stakeholders in understanding its overall health and performance.
*Pros: *
